Pharmacogenomics to Predict Responses to SGLT2 Inhibitors

Trial Profile

Pharmacogenomics to Predict Responses to SGLT2 Inhibitors

Phase of Trial: Phase I

Latest Information Update: 29 Aug 2017

At a glance

  • Drugs Canagliflozin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacodynamics; Pharmacogenomic
  • Most Recent Events

    • 22 Aug 2017 Status changed from not yet recruiting to recruiting.
    • 10 Jun 2017 Biomarkers information updated
    • 24 Sep 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top